Author:
Bero Lisa A.,Rennie Drummond
Abstract
AbstractTo practice evidence-based medicine, physicians need data on the clinical effectiveness, toxicity, convenience, and cost of new drugs compared with available alternatives. We give examples of published drug studies that are defective, sometimes because pharmaceutical industry funding has affected their content and quality. We make recommendations on how to avoid these defects.
Publisher
Cambridge University Press (CUP)
Reference146 articles.
1. Review of company postmarketing surveillance studies.
2. The FDA's Critique of the Anturane Reinfarction Trial
3. 128. Temple R. Difficulties in evaluating positive control trials. Biopharmaceutical Section Proceedings of the American Statistical Association, 1983, 1–7.
Cited by
169 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献